Blood test may predict best dose for nerve disorder treatment
NCT ID NCT04356781
First seen Feb 24, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study looked at 20 adults with chronic nerve conditions (CIDP or MMN) who were starting IVIg treatment. Researchers wanted to see if changes in IgG levels in the blood after the first dose could help predict the best long-term dose for each patient. The goal is to make dosing more precise, reduce side effects, and lower costs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Walton Centre NHS Foundation Trust
Liverpool, Merseyside, L9 7LJ, United Kingdom
Conditions
Explore the condition pages connected to this study.